Elbez Y - Search Results

1

Optimal or standard control of systolic and diastolic blood pressure across risk factor categories in patients with chronic coronary syndromes.

Vidal-Petiot E, Elbez Y, Mesnier J, Ducrocq G, Ford I, Tendera M, Ferrari R, Tardif JC, Fox KM, Steg PG. Vidal-Petiot E, et al. Among authors: elbez y. Eur J Prev Cardiol. 2023 Aug 1;30(10):935-947. doi: 10.1093/eurjpc/zwad004. Eur J Prev Cardiol. 2023. PMID: 36617264 Free article.

2

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M. Alten R, et al. Among authors: elbez y. RMD Open. 2017 Dec 29;3(2):e000538. doi: 10.1136/rmdopen-2017-000538. eCollection 2017. RMD Open. 2017. PMID: 29435360 Free PMC article.

3

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis.

Mease PJ, McInnes IB, Strand V, FitzGerald O, Ahmad HA, Elbez Y, Banerjee S. Mease PJ, et al. Among authors: elbez y. Rheumatol Int. 2020 Jul;40(7):1021-1028. doi: 10.1007/s00296-020-04564-x. Epub 2020 Apr 30. Rheumatol Int. 2020. PMID: 32356115 Free PMC article. Clinical Trial.

4

Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.

Westhovens R, Connolly SE, Margaux J, Vanden Berghe M, Maertens M, Van den Berghe M, Elbez Y, Chartier M, Baeke F, Robert S, Malaise M. Westhovens R, et al. Among authors: elbez y. Rheumatol Int. 2020 Sep;40(9):1409-1421. doi: 10.1007/s00296-020-04619-z. Epub 2020 Jun 17. Rheumatol Int. 2020. PMID: 32556473 Free PMC article.

5

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.

Ahmad HA, Baker JF, Conaghan PG, Emery P, Huizinga TWJ, Elbez Y, Banerjee S, Østergaard M. Ahmad HA, et al. Among authors: elbez y. Arthritis Res Ther. 2022 Feb 16;24(1):47. doi: 10.1186/s13075-022-02735-8. Arthritis Res Ther. 2022. PMID: 35172859 Free PMC article. Clinical Trial.

6

Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study.

Durez P, Westhovens R, Baeke F, Elbez Y, Robert S, Ahmad HA. Durez P, et al. Among authors: elbez y. BMC Rheumatol. 2022 Apr 14;6(1):24. doi: 10.1186/s41927-022-00252-4. BMC Rheumatol. 2022. PMID: 35418172 Free PMC article.

7

Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.

Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G. Galeazzi M, et al. Among authors: elbez y. Clin Exp Rheumatol. 2018 Sep-Oct;36(5):935-936. Epub 2018 Mar 21. Clin Exp Rheumatol. 2018. PMID: 29600933 Free article. No abstract available.

8

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study.

Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, Le Bars M. Alten R, et al. Among authors: elbez y. RMD Open. 2016 Feb 15;2(1):e000228. doi: 10.1136/rmdopen-2015-000228. eCollection 2016. RMD Open. 2016. PMID: 26925253 Free PMC article.

9

Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.

Alten R, Feist E, Lorenz HM, Nüßlein H, Voll RE, Chartier M, Elbez Y, Rauch C. Alten R, et al. Among authors: elbez y. Clin Rheumatol. 2019 Nov;38(11):3049-3059. doi: 10.1007/s10067-019-04648-5. Epub 2019 Jul 12. Clin Rheumatol. 2019. PMID: 31300979

10

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C. Alten R, et al. Among authors: elbez y. Arthritis Res Ther. 2018 Jan 2;20(1):1. doi: 10.1186/s13075-017-1488-5. Arthritis Res Ther. 2018. PMID: 29329602 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters